NO20063621L - Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet - Google Patents

Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet

Info

Publication number: NO20063621L
Authority: NO; Norway
Prior art keywords: alkyl; pyrazol; sulfonamide; diphenyl; derivatives
Prior art date: 2004-01-12

Application number

NO20063621A

Other languages

English (en)

Norwegian (no)

Inventor

Christian Congy

Francis Barth

Murielle Rinaldi-Carmona

Serge Martinez

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-12

Filing date

2006-08-10

Publication date

2006-10-10

2006-08-10 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2006-10-10 Publication of NO20063621L publication Critical patent/NO20063621L/no

Links

-1 1,5-diphenyl-1H-pyrazol-3-yl Chemical group 0.000 title 1
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 title 1
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 title 1
229940124530 sulfonamide Drugs 0.000 title 1
150000003456 sulfonamides Chemical class 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Anesthesiology (AREA)

NO20063621A 2004-01-12 2006-08-10 Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet NO20063621L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0400257A FR2864958B1 (fr)	2004-01-12	2004-01-12	Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
PCT/FR2005/000031 WO2005073197A1 (fr)	2004-01-12	2005-01-07	Derives de n-` (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1

Publications (1)

Publication Number	Publication Date
NO20063621L true NO20063621L (no)	2006-10-10

Family

ID=34684951

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063621A NO20063621L (no)	2004-01-12	2006-08-10	Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet

Country Status (31)

Country	Link
US (1)	US7294645B2 (pl)
EP (1)	EP1720837B1 (pl)
JP (1)	JP4723514B2 (pl)
KR (1)	KR20060105050A (pl)
CN (1)	CN1910157A (pl)
AR (1)	AR047096A1 (pl)
AT (1)	ATE465995T1 (pl)
AU (1)	AU2005209441B2 (pl)
CA (1)	CA2551141C (pl)
CR (1)	CR8468A (pl)
CY (1)	CY1110651T1 (pl)
DE (1)	DE602005020907D1 (pl)
DK (1)	DK1720837T3 (pl)
EC (1)	ECSP066695A (pl)
ES (1)	ES2344850T3 (pl)
FR (1)	FR2864958B1 (pl)
HR (1)	HRP20100283T8 (pl)
IL (1)	IL176710A0 (pl)
MA (1)	MA28422B1 (pl)
NO (1)	NO20063621L (pl)
NZ (1)	NZ548442A (pl)
PL (1)	PL1720837T3 (pl)
PT (1)	PT1720837E (pl)
RS (1)	RS51365B (pl)
RU (1)	RU2366657C2 (pl)
SI (1)	SI1720837T1 (pl)
TN (1)	TNSN06203A1 (pl)
TW (1)	TWI323255B (pl)
UA (1)	UA85079C2 (pl)
WO (1)	WO2005073197A1 (pl)
ZA (1)	ZA200605657B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7030141B2 (en) *	2001-11-29	2006-04-18	Christopher Franklin Bigge	Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2880023B1 (fr)	2004-12-23	2007-02-23	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2880890B1 (fr) *	2005-01-19	2007-03-30	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
FR2881744B1 (fr)	2005-02-09	2007-04-27	Sanofi Aventis Sa	Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2894579B1 (fr) *	2005-12-12	2008-01-18	Sanofi Aventis Sa	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
FR2894578B1 (fr) *	2005-12-12	2008-02-01	Sanofi Aventis Sa	Derives heterocycliques, leur preparation et leur application en therapeutique.
EP1829867A1 (en) *	2006-03-03	2007-09-05	Laboratorios Del Dr. Esteve, S.A.	Imidazole compounds having pharmaceutical activity towards the sigma receptor
FR2899899A1 (fr) *	2006-04-14	2007-10-19	Sanofi Aventis Sa	Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
DE602006014532D1 (de) *	2006-07-11	2010-07-08	Sanofi Aventis	N-Ä(1,5-diphenyl-1H-pyrazol-3-yl)methylÜsulfonamid-Derivate Antagonisten der CB1 Rezeptoren der Cannabinoide
US7297710B1 (en) *	2006-07-12	2007-11-20	Sanofi-Aventis	Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
JP2008019205A (ja) *	2006-07-12	2008-01-31	Sanofi-Aventis	Ｎ−［（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）メチル］スルホンアミド誘導体、その調製法および治療におけるその応用
WO2008062424A2 (en) *	2006-07-31	2008-05-29	Cadila Healthcare Limited	Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
US7875647B2 (en)	2006-09-29	2011-01-25	Green Cross Corporation	Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP1911747A1 (en) *	2006-10-11	2008-04-16	Laboratorios del Dr. Esteve S.A.	Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
FR2911136B1 (fr) *	2007-01-05	2009-02-20	Sanofi Aventis Sa	Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
FR2919184A1 (fr) *	2007-07-26	2009-01-30	Sanofi Aventis Sa	L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
BR112015003393A2 (pt)	2012-08-16	2017-07-04	Janssen Pharmaceutica Nv	pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
JP6250674B2 (ja)	2012-08-16	2017-12-20	ヤンセンファーマシューティカエヌ．ベー．	Ｎ型カルシウムチャネル遮断剤としてのピロロピラゾール
KR20150108384A (ko) *	2013-01-17	2015-09-25	에프. 호프만-라 로슈 아게	중추신경계 질병의 치료를 위한 옥시토신 수용체 작용제
US9453002B2 (en)	2013-08-16	2016-09-27	Janssen Pharmaceutica Nv	Substituted imidazoles as N-type calcium channel blockers
KR101685993B1 (ko) *	2014-05-15	2016-12-13	한국과학기술연구원	전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
EP3452036A4 (en)	2016-05-04	2019-11-06	Inmed Pharmaceuticals Inc.	USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND ASSOCIATED BINDING WEB DISEASES
EP3684353A4 (en)	2017-09-22	2021-06-23	Inmed Pharmaceuticals Inc.	TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
WO2022109292A1 (en) *	2020-11-20	2022-05-27	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Methods and materials for inhibiting cb1 activity
WO2025090587A1 (en)	2023-10-23	2025-05-01	Inmed Pharmaceuticals Inc.	Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2025090133A1 (en)	2023-10-23	2025-05-01	Inmed Pharmaceuticals Inc.	Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
RU2165542C2 (ru) *	1999-04-27	2001-04-20	Открытое акционерное общество "АВТОВАЗ"	Модульный агрегат топливоподачи системы питания двигателя транспортного средства

2004
- 2004-01-12 FR FR0400257A patent/FR2864958B1/fr not_active Expired - Fee Related
2005
- 2005-01-07 EP EP05717379A patent/EP1720837B1/fr not_active Expired - Lifetime
- 2005-01-07 CA CA2551141A patent/CA2551141C/fr not_active Expired - Fee Related
- 2005-01-07 DK DK05717379.1T patent/DK1720837T3/da active
- 2005-01-07 RU RU2006129297/04A patent/RU2366657C2/ru not_active IP Right Cessation
- 2005-01-07 NZ NZ548442A patent/NZ548442A/en not_active IP Right Cessation
- 2005-01-07 DE DE602005020907T patent/DE602005020907D1/de not_active Expired - Lifetime
- 2005-01-07 WO PCT/FR2005/000031 patent/WO2005073197A1/fr not_active Ceased
- 2005-01-07 KR KR1020067016046A patent/KR20060105050A/ko not_active Ceased
- 2005-01-07 JP JP2006548341A patent/JP4723514B2/ja not_active Expired - Fee Related
- 2005-01-07 ES ES05717379T patent/ES2344850T3/es not_active Expired - Lifetime
- 2005-01-07 SI SI200531060T patent/SI1720837T1/sl unknown
- 2005-01-07 PL PL05717379T patent/PL1720837T3/pl unknown
- 2005-01-07 HR HR20100283T patent/HRP20100283T8/xx unknown
- 2005-01-07 PT PT05717379T patent/PT1720837E/pt unknown
- 2005-01-07 AU AU2005209441A patent/AU2005209441B2/en not_active Ceased
- 2005-01-07 CN CNA2005800022298A patent/CN1910157A/zh active Pending
- 2005-01-07 UA UAA200608995A patent/UA85079C2/ru unknown
- 2005-01-07 ZA ZA200605657A patent/ZA200605657B/xx unknown
- 2005-01-07 AT AT05717379T patent/ATE465995T1/de active
- 2005-01-07 RS RSP-2010/0336A patent/RS51365B/sr unknown
- 2005-01-10 AR ARP050100070A patent/AR047096A1/es unknown
- 2005-01-11 TW TW094100683A patent/TWI323255B/zh not_active IP Right Cessation
2006
- 2006-06-19 MA MA29118A patent/MA28422B1/fr unknown
- 2006-06-21 CR CR8468A patent/CR8468A/es unknown
- 2006-06-23 TN TNP2006000203A patent/TNSN06203A1/en unknown
- 2006-07-05 IL IL176710A patent/IL176710A0/en not_active IP Right Cessation
- 2006-07-06 US US11/428,928 patent/US7294645B2/en not_active Expired - Lifetime
- 2006-07-11 EC EC2006006695A patent/ECSP066695A/es unknown
- 2006-08-10 NO NO20063621A patent/NO20063621L/no not_active Application Discontinuation
2010
- 2010-06-03 CY CY20101100491T patent/CY1110651T1/el unknown

Also Published As

Publication number	Publication date
US7294645B2 (en)	2007-11-13
TW200535135A (en)	2005-11-01
WO2005073197A1 (fr)	2005-08-11
AU2005209441B2 (en)	2010-12-23
HRP20100283T8 (hr)	2010-10-31
UA85079C2 (en)	2008-12-25
PT1720837E (pt)	2010-05-14
JP4723514B2 (ja)	2011-07-13
PL1720837T3 (pl)	2010-09-30
SI1720837T1 (sl)	2010-08-31
HRP20100283T1 (hr)	2010-08-31
AU2005209441A1 (en)	2005-08-11
EP1720837B1 (fr)	2010-04-28
DE602005020907D1 (de)	2010-06-10
ATE465995T1 (de)	2010-05-15
FR2864958B1 (fr)	2006-02-24
JP2007517839A (ja)	2007-07-05
DK1720837T3 (da)	2010-08-23
CN1910157A (zh)	2007-02-07
CA2551141A1 (fr)	2005-08-11
RS51365B (sr)	2011-02-28
CY1110651T1 (el)	2015-06-10
US20070021486A1 (en)	2007-01-25
RU2366657C2 (ru)	2009-09-10
AR047096A1 (es)	2006-01-04
IL176710A0 (en)	2006-10-31
CR8468A (es)	2007-03-06
MA28422B1 (fr)	2007-02-01
ECSP066695A (es)	2006-10-31
FR2864958A1 (fr)	2005-07-15
KR20060105050A (ko)	2006-10-09
TWI323255B (en)	2010-04-11
TNSN06203A1 (en)	2007-11-15
CA2551141C (fr)	2011-06-07
NZ548442A (en)	2009-10-30
ZA200605657B (en)	2007-12-27
EP1720837A1 (fr)	2006-11-15
ES2344850T3 (es)	2010-09-08
RU2006129297A (ru)	2008-02-20

Legal Events

Date	Code	Title	Description
2013-08-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
UA85079C2 (en)	2008-12-25	Derivatives of n-(1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
NO20082136L (no)	2008-06-30	1,5-substituerte indol-2-yl-amidderivater
NO20063599L (no)	2006-10-27	Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20034289L (no)	2003-11-28	N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren
NO20091553L (no)	2009-04-20	Fenylderivater og deres anvendelse som immunmodulatorer
NO20070336L (no)	2007-02-13	Indolderivater som histamin-reseptorantagonister
NO20075082L (no)	2007-10-31	Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091299L (no)	2009-04-29	Substituerte sulfonamidderivater
NO20066055L (no)	2007-01-24	Pyridinderivater
ATE496620T1 (de)	2011-02-15	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20072963L (no)	2007-08-03	5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20054082L (no)	2005-11-04	Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20071593L (no)	2007-05-22	Pyrimidinderivater
NO20081001L (no)	2008-03-25	Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20073287L (no)	2007-09-25	2,5 og 2,6-disubstituerte benzazol-analoger som proteinkinaseinhibitorer
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
NO20082939L (no)	2008-09-17	Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
NO20092058L (no)	2009-09-17	Heteroaryl pyrrolidinyl ketonderivater
NO20091052L (no)	2009-04-06	Diaryleterderivater og anvendelser derav
ATE355265T1 (de)	2006-03-15	Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
NO20080033L (no)	2008-01-03	Kinolinderivater som NK3-antagonister
PT1877364E (pt)	2009-07-09	Derivados fenilacetileno com afinidade para o receptor mglur5
NO20050666L (no)	2005-03-11	2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20082130L (no)	2008-06-23	3-Amino-1-arylpropylindoler og aza-substituerte indoler